Proceedings IMWA 2010

Abstract A research-grade passive treatment system was constructed to receive 1000 L/minute of mine water from abandoned boreholes (pH 5.95, net alkalinity 29 mg/L CaCO₃, Fe 192 mg/L, Zn 11 mg/L, Cd 17 μg/L, Pb 60 μg/L and As 64 μg/L). The 2-ha system includes an oxidation pond followed by parallel treatment trains of aerobic wetlands, vertical flow bioreactors, re-aeration ponds, and horizontal-flow limestone beds and a final polishing wetland. Final effluent waters had pH >7 and contained < 1 mg/L total Fe and < 0.1 mg/L total Zn, with concentrations of Cd, Pb and As below detectable limits. Key Words hard rock mining, metal mining, acid mine drainage, natural treatment systems Introduction This paper describes the initial evaluation of an innovative, ecologically engineered passive system designed to treat abandoned ferruginous Pb-Zn mine waters at the Tar Creek Superfund Site, part of the historic Tri-State Mining District (TSMD) of Oklahoma, Kansas and Missouri, USA. Significant quantities of Pb and Zn were produced from the TSMD from the 1890s through the 1960s. By the early 1970s when mining ceased, two and nine million tons of Pb and Zn, respectively, had been produced During mining, large capacity dewatering operations pumped approximately 50,000 m³ d⁻¹ of water from the mines (Reed et al. 1955). Upon decline and cessation of mining, groundwater began to accumulate in the mine voids. By late 1979, metal-rich waters began to discharge via artesian pressure into Tar Creek and its tributaries. The first documented discharges of mine drainage were at a location near southeast Commerce, OK (Oklahoma Water Resources Board 1983) and were subsequently identified for passive treatment implementation Methods For this study, periodic water quality and quantity data collection efforts for the subject discharges began in 1998, with regular monthly sampling beginning in 2004 and continuing to the present. The targeted discharges have circum-neutral pH (5.96 ± 0.06), total alkalinity of 405 ± 13 mg/L as CaCO₃ and combined flow rates of up to 1000 L/minute. Metals and sulfate concentrations are elevated above expected levels and degrade the receiving waters ). Design and construction details for the passive treatment system are summarized in Sydney, NS IMWA 2010 "Mine Water and Innovative Thinking" Wolkersdorfer & Freund Results and Discussion In the year of operation, the passive treatment system performed as designed from a water quality perspective ( Other metals of specific interest in these waters were Cd, Pb, and As. All three were removed to below detection limits (0.64, 19.5 and 22 µg/L, respectively) before the outflow of the second process units, presumably through sorptive processes. Although the vertical-flow bioreactors were designed to remove Cd and Pb as well as Zn, Cd and Pb rarely remained in measureable concentrations at this stage of the treatment system. The other trace metal found in significant concentrations in these waters was Ni. A small percentage (<10%) of Ni was removed through co-precipitation and sorption in Cell 1. However, the majority of Ni (≈ 95%) was removed via re- IMWA 2010 Sydney, NS "Mine Water and Innovative Thinking&quot

Hydrogen states in mixed-cation CuIn(1−x)GaxSe2 chalcopyrite alloys: a combined study by first-principles density-functional calculations and muon-spin spectroscopy

First-principles calculations were performed jointly with muon-spin (µSR) spectroscopy experiments in order to examine the electrical activity of hydrogen in mixed-cation chalcopyrite Cu(In1−x,Gax)Se2 (CIGS) alloys and other related compounds commonly used as absorbers in solar-cell technology. The study targeted the range of Ga concentrations most relevant in typical solar cells. By means of a hybridfunctional approach the charge-transition levels of hydrogen were determined and the evolution of the defect pinning level, E(+/–), was monitored as a function of the Ga content. The use of E(+/–) as a metric of the charge-neutrality level allowed the alignment of band structures, thus providing the band offsets between the CuInSe2 compound and the CIGS alloys. The µSR measurements in both thin-film and bulk CIGS materials confirmed that the positively-charged state is the thermodynamically stable configuration of hydrogen for p-type conditions. The interpretation of the µSR data further addressed the existence of a metastable quasi-atomic neutral configuration that was resolved from the calculations and led to a formation model for muon implantation

Pulsed laser deposition of chalcogenide sulfides from multi- and single-component targets: the non-stoichiometric material transfer

The mass transfer from target to films is incongruent for chalcogenide sulfides in contrast to the expectations of pulsed laser deposition (PLD) as a stoichiometric film growth process. Films produced from a CZTS (Cu2ZnSnS4) multi-component target have no Cu below a fluence threshold of 0.2 J/cm2, and the Cu content is also very low at low fluence from a single-component target. Above this threshold, the Cu content in the films increases almost linearly up to a value above the stoichiometric value, while the ratio of the concentration of the other metals Zn to Sn (Zn/Sn) remains constant. Films of a similar material CTS (Cu2SnS3) have been produced by PLD from a CTS target and exhibits a similar trend in the same fluence region. The results are discussed on the basis of solid-state data and the existing data from the literature

Nusinersen Versus Sham Control In Infantile-Onset Spinal Muscular Atrophy

BACKGROUND & para;& para;Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that modifies pre-messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein.& para;& para;METHODS & para;& para;We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy. The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurological Examination) and event-free survival (time to death or the use of permanent assisted ventilation). Secondary end points included over all survival and subgroup analyses of event-free survival according to disease duration at screening. Only the first primary end point was tested in a prespecified interim analysis. To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final analysis.& para;& para;RESULTS & para;& para;In the interim analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41 %] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial. In the final analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005). The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen. The incidence and severity of adverse events were similar in the two groups.& para;& para;CONCLUSIONS & para;& para;Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group. Early treatment may be necessary to maximize the benefit of the drug.Wo

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

International audienceBACKGROUND Nusinersen is an antisense oligonucleotide drug that modulates pre-messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy (SMA). METHODS We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusinersen in 126 children with SMA who had symptom onset after 6 months of age. The children were randomly assigned, in a 2: 1 ratio, to undergo intrathecal administration of nusinersen at a dose of 12 mg (nusinersen group) or a sham procedure (control group) on days 1, 29, 85, and 274. The primary end point was the least-squares mean change from baseline in the Hammersmith Functional Motor Scale-Expanded (HFMSE) score at 15 months of treatment; HFMSE scores range from 0 to 66, with higher scores indicating better motor function. Secondary end points included the percentage of children with a clinically meaningful increase from baseline in the HFMSE score (>= 3 points), an outcome that indicates improvement in at least two motor skills. RESULTS In the prespecified interim analysis, there was a least-squares mean increase from baseline to month 15 in the HFMSE score in the nusinersen group (by 4.0 points) and a least-squares mean decrease in the control group (by -1.9 points), with a significant between-group difference favoring nusinersen (least-squares mean difference in change, 5.9 points; 95% confidence interval, 3.7 to 8.1; P< 0.001). This result prompted early termination of the trial. Results of the final analysis were consistent with results of the interim analysis. In the final analysis, 57% of the children in the nusinersen group as compared with 26% in the control group had an increase from baseline to month 15 in the HFMSE score of at least 3 points (P< 0.001), and the overall incidence of adverse events was similar in the nusinersen group and the control group (93% and 100%, respectively). CONCLUSIONS Among children with later-onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared with those in the control group. (Funded by Biogen and Ionis Pharmaceuticals; CHERISH ClinicalTrials. gov number, NCT02292537.